Please login to the form below

Spark Therapeutics

This page shows the latest Spark Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Roche reports continued growth in Q3, despite biosimilar competition

This “progress of our product pipeline” likely hints to Roche’s $4.3bn acquisition of Spark Therapeutics earlier this year, which has faced continued delays. ... This is mainly due to ongoing scrutiny from regulatory authorities, with the main

Latest news

Allergan investors back AbbVie deal, but is a tax charge looming?

The FTC seems to be taking a tougher line on antitrust approvals in pharma at the moment – as can be seen with Roche’s much-delayed $4.3bn takeover of Spark ... Therapeutics and Bristol-Myers Squibb’s forced divestiture of psoriasis drug Otezla
Novo Nordisk, bluebird team up to develop haemophilia A therapies

Spark Therapeutics, the subject of a protracted takeover attempt by Roche, has a haemophilia A gene therapy in late-phase development.
NICE backs NHS use of Novartis’ gene therapy Luxturna

Novartis secured rights to the therapy outside the US from its original developer Spark Therapeutics last year shortly after the biotech won FDA approval for Luxturna as the first directly-administered ... Since then Roche has been attempting to take
Pfizer goes big on gene therapy with $500m facility spend

That was followed swiftly by a partnership with Spark Therapeutics that brought in a clinical-stage haemophilia B therapy now in phase 3 testing, and another deal with Sangamo for a ... Just this year, for example, Roche agreed to buy Spark for
Roche reveals yet another Spark takeover delay

Are concerns about haemophilia dominance the cause? Roche has put back the expected completion date for its takeover of gene therapy company Spark Therapeutics for another three months, leaving investors asking ... about anticompetitive issues that

More from news
Approximately 14 fully matching, plus 32 partially matching documents found.

Latest Intelligence

Bluebird: on a mission to ‘recode’ the DNA of healthcare

Meanwhile, Spark Therapeutics’ Luxturna for a hereditary eye disease (marketed by Novartis in Europe) costs around $425, 000 per eye, bringing it close to that $1m mark. ... Fellow US gene therapy company Spark was acquired by Roche for $4.3bn in
Drug launches to watch in 2019

1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... Unlike fellow Boston, MA-based gene therapy company Spark
The European Medicines Agency: PRIME’d for access?

sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all ... Those prices pale in comparison though when
Bluebird Bio: on the cusp of a gene therapy revolution

drugs, Novartis’ Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’ gene therapy Luxturna all reaching the market last year. ... of a more stable adeno-associated virus (AAV) – which now forms the basis of Spark Therapeutics’ drugs and,
Health on instalment

For example, Luxturna maker Spark Therapeutics approached a commercial payer with a pay-for-performance option.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

Industry appointments

Sigilon has already reached certain milestones for its Living Therapeutics product platform, including its Afibromer technology, which represents a new class of breakthrough implantable biomaterials. ... Vivaldi has more than 25 years’ experience and

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Account Manager / Account Director - MedComms - London: Highly competitive salary &package

Senior Copywriter: Salary TBC

Account Director, Medical Education: Salary TBC

Senior Medical Writer: Salary TBC

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Editorial Assistants - Medical Communications agency - Cheshire: Excellent Remuneration Package

Experienced / Senior Medical Writer - Excellent Progression Oppo...: Excellent Salary and Benefits on offer

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior Medical Writer – Medical Communications – North West – In...: Excellent Remuneration Package

Senior / Principal Medical Writers wanted - MedComms - Various U...: Excellent Remuneration Packages

Subscribe to our email news alerts

PMHub

Add my company

Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...